We are live on ! Find out more
IMNP

Immune Pharmaceuticals Inc.
IMNP

Delisted

IMNP was delisted on the 25th of July, 2018.

Back to rankings

14 hedge funds and large institutions have $912K invested in Immune Pharmaceuticals Inc. in 2016 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 3

8% more capital invested

Capital invested by funds: $845K → $912K (+$67K)

0% more funds holding

Funds holding: 14 → 14 (0)

0% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 3

Holders
14
Holders Change
–
Holders Change %
0%
% of All Funds
0.35%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
6
Reduced
3
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$390K
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$42K
3
TSS
Two Sigma Securities
New York
+$26.2K
4
AG
Advisor Group
Arizona
+$15.4K
5
UBS Group
UBS Group
Switzerland
+$7.52K

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$43K
2
Goldman Sachs
Goldman Sachs
New York
-$24.8K
3
VKH
Virtu KCG Holdings
New York
-$19.5K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$5.62K
5
IFS
Ifrah Financial Services
Arkansas
-$4K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$725K +$390K +94,898 +91%
Geode Capital Management
2
Geode Capital Management
Massachusetts
$81K +$42K +10,217 +84%
TSS
3
Two Sigma Securities
New York
$29K +$26.2K +6,375 +405%
UBS Group
4
UBS Group
Switzerland
$18K +$7.52K +1,831 +58%
AG
5
Advisor Group
Arizona
$14K +$15.4K +3,750 New
Susquehanna International Group
6
Susquehanna International Group
Pennsylvania
$11K -$5.62K -1,367 -31%
VKH
7
Virtu KCG Holdings
New York
$10K -$19.5K -4,755 -63%
Goldman Sachs
8
Goldman Sachs
New York
$7K -$24.8K -6,032 -77%
EEG
9
E.E. Geduld
$5K – – –
LTFS
10
Ladenburg Thalmann Financial Services
Florida
$5K +$5.24K +1,275 +1,275%
Citadel Advisors
11
Citadel Advisors
Florida
$4K +$4.76K +1,160 New
BFA
12
BlackRock Fund Advisors
California
$2K +$444 +108 +32%
Creative Planning
13
Creative Planning
Kansas
$1K +$1.03K +250 New
Renaissance Technologies
14
Renaissance Technologies
New York
– -$43K -7,625 Closed
IFS
15
Ifrah Financial Services
Arkansas
– -$4K -650 Closed

IMNP Hedge Fund Activity: Q4 2016 in Review

14 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Immune Pharmaceuticals Inc. (IMNP) for Q4 2016, worth a combined $912K — up 7.9% from $845K a quarter earlier.

Fund positioning in IMNP was balanced in Q4 2016: 3 funds opened new positions, 3 closed out, 6 added to existing stakes and 3 trimmed.

The largest buyer was Vanguard Group, adding an estimated $390K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $43K sold.

  • 14 institutional investors held Immune Pharmaceuticals Inc. (IMNP) as of Q4 2016, unchanged from Q3 2016.
  • Funds reported $912K of Immune Pharmaceuticals Inc. stock for Q4 2016, up 7.9% quarter-over-quarter.
  • 3 funds opened new Immune Pharmaceuticals Inc. positions in Q4 2016 and 3 closed out, a net change of 0 holders.
  • The largest Immune Pharmaceuticals Inc. buyer in Q4 2016 was Vanguard Group, an estimated $390K added.
  • The largest Immune Pharmaceuticals Inc. seller in Q4 2016 was Renaissance Technologies, an estimated $43K sold.

Based on aggregated 13F filings for Q4 2016.